A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Balsalazide Disodium

Aminosalicylate class · 5 generic manufacturers · 5 ANDAs filed at FDA.

First FDA approval2007-12-28
Generic availableYes · 5 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$27.8M in CY2024 Part D spend160K claims · 44K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.372/unit
6 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.372
Across all dosage forms in distribution.
Highest NADAC
$0.372
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Balsalazide Disodium used for?

Balsalazide Disodium is a Aminosalicylate medication tracked in Medicare Part D.

Is there a generic for Balsalazide Disodium?

Yes. 5 ANDAs filed at FDA, 5 generic manufacturers currently shipping.

How much does my plan pay for Balsalazide Disodium?

Across 329 Part D plans, Balsalazide Disodium averages $0.372/unit (NADAC). Lowest available: $0.372/unit. Highest in distribution: $0.372/unit.

Is Balsalazide Disodium on the FDA shortage list?

No. Balsalazide Disodium is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Aminosalicylate2 alternatives in D1
01
Mesalamine
Brand: APRISO
$0.104Lowest NADAC
23Generic mfrs
$454.7MCY24 Part D spend
Compare →
02
Sulfasalazine
Brand: Azulfidine
$0.197Lowest NADAC
4Generic mfrs
$29.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (6 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.